Immune Checkpoint Inhibitors (ICIs) are successful in 40% of cancer patients but are invasive and time-consuming. Scientists at Israel’s Technion Institute have developed a tool that predicts the response based on the metabolic activity in the immune system cells. (See … Continue reading →

Israel’s Oncohost is working with Israel’s Technion to develop cutting-edge technology to characterize, analyze and predict patient response and resistance to cancer therapy. This enables personalized treatment strategies with improved outcomes & reduced side effects. http://oncohost.com/ https://www.jpost.com/Jpost-Tech/Hillels-Tech-Corner-Cancer-treatment-personalized-610032

Ben-Gurion University researchers have partnered Israel’s OncoHost to develop a biosensor that safely predicts if anti-PD1 therapy may cure a specific cancer patient. The leading immune checkpoint inhibitor (ICI) therapy is invasive and other treatments may be better. (see also … Continue reading →

The UK National Health Service (NHS) is to trial the blood test from Israel’s OncoHost (see here previously) that predicts how well cancer patients will respond to immunotherapy treatment. Trials will focus on patients with advanced melanoma or non-small cell … Continue reading →

Israel’s OncoHost (reported here previously) has achieved about 90% accuracy in predicting how melanoma and lung cancer patients respond to various therapies. And now Israeli Nobel Prize winner Professor Aaron Ciechanover has joined OncoHost’s scientific advisory board. https://www.prnewswire.com/il/news-releases/oncohost-welcomes-nobel-prize-winner-to-scientific-advisory-board-301205142.html https://jitc.bmj.com/content/8/Suppl_3/A11.2 https://www.timesofisrael.com/spotlight/nobel-prizewinner-ciechanover-hails-much-more-precise-cancer-treatment/ … Continue reading →

Israel’s Oncohost (reported here previously) presented the results of its latest proteomic (proteins) cancer study to the Society for Immunotherapy of Cancer’s (SITC). Oncohost’s PROphet host response profiling platform can predict the best therapy to use for specific cancer patients. … Continue reading →

Israeli biotech Nucleai (reported here previously) has progressed from merely analyzing biopsies. It now uses its computer vision and machine learning to study the characteristics of tumors, helping predict which cancer patients will respond to which immunotherapy medication. https://www.timesofisrael.com/nucleai-raises-6-5-million-to-help-pharma-firms-match-drugs-to-cancer-patients/

Israeli scientists are frequently finding new ways of personalizing cancer treatments. Some are based on genetics (see here) or proteins expressed by the body (see here). Now Weizmann Institute researchers are devising a system to predict how patients will respond … Continue reading →

Berlin’s caresyntax, has launched an R&D partnership with the ARC (Accelerate, Redesign, Collaborate) complex at Israel’s Sheba Medical Center. They will use Artificial Intelligence to develop algorithms for predicting responses and outcomes for cancer treatment procedures. https://www.businesswire.com/news/home/20200107005204/en/caresyntax-ARC-Sheba-Medical-Center-Launch-Collaboration https://caresyntax.com/news/caresyntax-sheba-medical-launch-collaboration/

Researchers at Tel Aviv University have developed a computerised genome-scale model of cancer cell metabolism which can help predict which treatments patients will have an effective response to. http://www.israelnationalnews.com/News/News.aspx/147068